Masaki Shimoji

Hiroshi Mizuuchi1
Tetsuya Mitsudomi1
Kazuko Sakai1
1Hiroshi Mizuuchi
1Tetsuya Mitsudomi
1Kazuko Sakai
1Yoshitaka Sekido
Learn More
Mutant selective epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as rociletinib and AZD9291, are effective for tumors with T790M secondary mutation that become refractory to first-generation EGFR-TKI. However, acquired resistance to these prospective drugs is anticipated considering the high adaptability of cancer cells and the(More)
  • 1